



Moorfields
Eye Charity



Impact Report 2022

We believe people’s sight matters

At Moorfields Eye Charity, we support pioneering eye health and the life-changing work at Moorfields Eye Hospital NHS Foundation Trust (Moorfields) and the UCL Institute of Ophthalmology (UCL) – increasing our understanding of eye conditions, speeding up diagnoses and bringing new treatments to people with sight loss.

One in five of us will live with sight loss in our lifetime. The number of people in the UK with sight loss is set to increase dramatically in the future. By 2050, it will double to over four million [1]. That’s why we invest in research and innovation, the best patient care and world-class training. And it’s why we’re a partner in realising Oriel, the centre for advancing eye health, benefitting people in the UK and worldwide.

Our strategy outlines five main objectives to:

- 1 Create a world-class integrated centre for advancing eye health, teaching and research in 2026-2027
- 2 Be the leading charity for research into eye health
- 3 Support innovation in patient care, enhancing the patient experience
- 4 Support sharing of knowledge and development of people’s expertise
- 5 Shape national policy to increase resources allocated to eye health



Mission

Improving eye health by funding innovation in research, education and care to benefit Moorfields’ patients.



Vision

Moorfields Eye Charity’s support enables Moorfields and UCL to provide world-leading eye care, research and education from the Oriel centre, benefitting patients across the UK and globally.



Our strategy 2021-2027

Our six year strategy outlines our ambitious objectives for the charity and our role supporting the work of Moorfields and UCL to benefit Moorfields’ patients. There’s an additional emphasis on innovation in clinical care and staff wellbeing and development.

Robert Dufton
Chief executive
Moorfields Eye Charity

It’s been a year in which Covid-19 continued to present challenges and when new digital innovations were embedded in service delivery. There’s also been a renewed focus on research and the opportunities ahead. We’re proud to fund Moorfields and UCL: supporting NHS staff to provide better patient care and researchers to discover new treatments and cures, and jointly helping prepare for the future demands of eye health globally with Oriel.

This impact report represents our work in the financial year to 31 March 2022. Over the last year, we’ve awarded over £6 million in grants to support innovation in research, care and education at Moorfields and UCL.

It was a year of major Oriel milestones with more philanthropic commitments, submission of the Moorfields’ Full Business Case to HM Treasury for approval, and exchange of conditional contracts with the preferred developer of the Moorfields and UCL sites.

Thanks to your support we’ve seen advances in research we’re funding including into inherited eye diseases and use of AI in eye health. We’ve also seen the benefits to patients’ wellbeing

with our support of the counselling service, giving children and their families emotional help.

We continue to fund researchers at different stages of their careers and we’re very proud that many receive prizes which further raise the profile of their work.

Along with other members, we endorsed the Association of Medical Research Charities’ #ResearchAtRisk campaign. This has led to the government starting to provide additional support to research charities.


Thank you to everyone who supports us – it makes a huge difference to the work of researchers and clinicians, and to the lives of patients in the UK and globally.

Our achievements

Moorfields and its academic partner UCL have an international reputation for research into eye conditions, with a world-leading ophthalmic research programme.

This translates into the best treatment and care for patients at Moorfields and training for eye specialists including clinicians from around the world.

Moorfields Eye Charity supports this unique partnership as the main fundraising and grant-making charity, and is a partner with Moorfields and UCL in realising Oriel – the planned world-leading centre for advancing eye health, opening in 2026-2027.





Objective 1: Creating a world-class integrated facility

We're working in partnership with Moorfields and UCL to create Oriel, a new world-class integrated centre for advancing clinical care, teaching and research, opening in 2026-2027.

Oriel, the joint initiative between Moorfields, UCL and Moorfields Eye Charity will establish the world-leading centre for advancing eye health. It reached major milestones over the last year and moves us closer to the opening of this new state-of-the-art facility which will harness Moorfields' and UCL's expertise under one roof and deliver the highest-quality eye care, research and education to benefit patients in the UK and worldwide.

Oriel will see services move from the current premises near Old Street, Islington to a new, integrated centre on the St Pancras Hospital site in Camden. With an ageing population, the demand for eye health care is forecast to increase. The integration of clinical care, research and education at Oriel will deliver new techniques and treatments to help meet the demand.

Philanthropy is critical to achieving our ambitious plans. Thank you to donors who have committed your support to date - we're immensely grateful, and thank you to those of you in discussion with us about how you can support Oriel.

Key milestones reached

Plans for the new global centre for advancing eye health have taken significant steps forward, with the co-design of the building progressing with patients and staff. Derwent London exchanged conditional contracts with Moorfields and UCL to buy the sites on City Road and Bath Street.

The Mayor of London approved plans for Oriel, with final planning permission expected from Camden Council this summer. UCL's and Moorfields' Full Business Cases have been approved by the UCL council and Moorfields' board and membership council, and Moorfields' business case has been submitted for review by regulators and HM Treasury.

Philanthropy

The charity, in partnership with UCL, is committed to raising £100 million (£75 million capital and £25 million for research and education) to make Oriel a reality. The campaign has raised over £45 million in capital commitments to date.

We are pleased to have formalised commitments from major donors and are having conversations with a number of potential donors interested in supporting Oriel.



Designing for the future

The building has been co-designed with patients, staff and people with sight loss. At the building’s heart, the proposal is to have a central atrium, a light-filled space called the ‘Oriel’. This is the social heart of the building which links clinical, research and education spaces enabling greater integration and bringing new discoveries to patients quicker than ever before.

The building will host outpatient services, day-surgery and recovery areas, patient support services, dedicated lab space for research, clinical trials and innovation, and education and conference space.

The interior has been designed by users including people with disabilities and sight loss through innovative use of material, colour and technology.

What’s next and the opening

Moorfields’ Full Business Case will be reviewed by HM Treasury for approval, with a decision expected in the autumn. The appointment of a building contractor will follow subject to approvals. Construction starts in 2023 alongside community engagement, donor events and an annual Oriel exhibition up until the opening in 2026-2027.

This is a once-in-a-century opportunity to implement radically new ways of working which will change the experience for researchers, staff, visitors and patients. The integration of eye care, research and education to create a shared space for scientific discovery and patient treatment will have a far-reaching impact.




SeeAbility has been involved with Oriel from the outset and our environmental suggestions have been taken on board. For blind and partially sighted people, the additional space will enable the use of technological wayfinding services which will increase personal independence.

Wayne Chapman - London eye care champion from national charity SeeAbility and a member of the Oriel partner advisory group

We are delighted to be supporting Moorfields Eye Charity and partners Moorfields Eye Hospital NHS Foundation Trust and UCL, which is helping to create a new facility, purpose-built for the future, that will enable Moorfields to combine clinical care, education, and research. This is a great opportunity to establish a world-leading centre for eye health, harnessing new technologies to accelerate research breakthroughs, and transform the patient experience. The facility is addressing a growing demand for eye care, and is helping patients at Moorfields and throughout the world.

Douglas Griffiths, President of Oak Foundation




Objective 2: Be the leading charity for research into eye health

Moorfields Eye Charity supports the pioneering work of Moorfields and UCL to make new discoveries and turn new knowledge into treatments to improve eye health and outcomes for patients of Moorfields and people globally. We collaborate with other funders to maximise research funding for eye health.

Improving treatments for glaucoma

Glaucoma is an eye disease where high pressure in the eye causes damage to the optic nerve. If left untreated, glaucoma can lead to vision loss. The LiGHT trial (Laser in Glaucoma and Ocular Hypertension Trial) explored new ways of treating glaucoma. It has led to changes in clinical guidelines on how glaucoma patients are treated. Moorfields Eye Charity has invested in the extension of this research to maximise outcomes from the trial.


The only known way to manage glaucoma is to lower the pressure within the eye. This can be done using eye drops, laser treatment or surgery. These treatments may not be as effective on some patients as others, and eye drops for example can cause unpleasant side effects such as irritation.



£4.4 million funding awarded to research projects



44 research projects funded



1.3 million people over age 40 in the UK have high eye pressure [2]

Trial outcomes changing practice

The LiGHT trial is a multicentre randomised controlled trial led by Professor Gus Gazzard, director of the glaucoma service at Moorfields Eye Hospital, and professor in ophthalmology, glaucoma studies at UCL London. The trial compared laser treatment to eye drops in newly diagnosed patients.

This trial was a pivotal study that led to the change in the National Institute for Health and Care Excellence (NICE) guidelines [2]. NICE now recommends selective laser trabeculoplasty (SLT) as the first line of treatment for newly diagnosed ocular hypertension and open-angle glaucoma patients.



3 out of 4 patients having laser treatment did not need any drops to control their eye pressure.

Maximising impact and outcomes of the LiGHT trial

Glaucoma is a chronic disease. Therefore, monitoring participants from the LiGHT trial in a controlled way for an extended period of time and where possible collecting blood samples for genetic testing, will help add great depth and breadth of research outcomes. The monitoring for another three years provided more detail on the use of laser treatment to control ocular pressure over an extended time.

The charity also funded a blood biobank, a resource to collate blood samples from participants from the LiGHT trial, all of whom gave consent. This will help further research into the genetics of glaucoma and how it affects disease progression and responses to treatments.

Looking beyond the UK, the charity has funded Professor Gazzard to lead a sister LiGHT trial in China where the three-year data is now being analysed.



“ We’re very pleased to have this long-term data on SLT effectiveness in controlling glaucoma and ocular hypertension. It will be used by clinicians to support treatment decisions. It shows the advantages of SLT over eye drops for long term care with reduced sight deterioration and less likelihood of surgery. ”

Professor Gus Gazzard

Article continues from page 11



Optometrists lead the way

Moorfields Eye Charity funded a study looking at the feasibility of and attitudes towards optometrists delivering SLT treatment for glaucoma patients. It gathered the views of key stakeholders including ophthalmologists, optometrists and patients, with their findings being published and presented at medical conferences. This study supports delivery of SLT by an optometrist, provided it is within an NHS clinical setting and the professional receives suitable training. **The charity is proud to support research which is having widespread impact on the treatment of glaucoma.**

■ **Due to the high number of optometrists involved, we're in a perfect position to deliver this service and care efficiently. With robust training protocols and governance - there is the potential for a shift in service delivery.** ■■

Dr Evgenia Konstantakopoulou, Research optometrist, Moorfields Eye Hospital

Partnerships changing eye health

We're involved with a growing number of partnerships including with the National Institute for Health Research (NIHR), Diabetes UK and Fight for Sight and are seeing the benefits of these collaborations on Moorfields' and UCL's work, on the broader eye health sector and on the lives of people with sight loss.

We partner with the NIHR



1 in 7 grants awarded by AMRC members were funded in collaboration with other organisations [3]

to invest in training and development opportunities for future leaders. We've awarded the first joint NIHR Moorfields Eye Charity Advanced Fellowship to Dr Patrick Yu Wai Man. He aims to improve the way inherited diseases that damage the optic nerve are managed and how treatments are evaluated.

Dr Yu Wai Man and colleagues have already successfully used gene therapy to replace the defective gene that causes Leber hereditary optic neuropathy in patients carrying a specific mutation. Results so far show that those who were treated within one year of being affected



experienced significant improvement in their vision. These results were published in Science Translational Medicine [4]. We're also very pleased to be funding research jointly with Fight for Sight into inherited retinal disease and co-funding research with Diabetes UK which aims to help guide future management for patients with diabetic retinopathy.

Lord Drayson – patient story

What's your connection to Moorfields?

I have been a patient of Moorfields since I was a baby - in fact I was the youngest person to receive a prosthetic eye at the time.

What does Moorfields mean to you?

Simply the world's best eye hospital - staffed by wonderfully caring and committed people.

Why is it important to you for the charity to be investing in research?

It is vital that Moorfields remains at the forefront of medical research so that it is able to provide the best possible care for its patients. The eye is one of the most complex organs of the body and there is a lot that we still do not understand about diseases of the eye, many of which can have a catastrophic effect on quality of life and especially when they affect young people.

There is something about eyes that makes them particularly precious and personal, windows to the soul as they have been described. It is only through medical research that we deepen our understanding to prevent and treat eye disease.

The Drayson Foundation generously supports research into 3D printing of prosthetic eyes at Moorfields Eye Hospital and UCL.



Syreeta Walker – patient story

What's your connection to Moorfields?

Many years ago when I was only 19, I was referred to Moorfields and diagnosed with glaucoma. The doctors explained to me what it was and the treatment needed to help manage it.

What does Moorfields mean to you?

Moorfields above all means hope. It can mean hope and bring hope to many people who are in danger of losing their sight or who need that extra care to manage their eye conditions.

Why is it important to you for the charity to be investing in research?

Research is so important. It's imperative more research is done, especially into glaucoma. Many young women want to know more about the effects of medication such as eye drops.

Syreeta supports the charity by donating a percentage of the proceeds from her Brixton Candle Company.





Objective 3: Supporting patient care

We support the development and wellbeing of Moorfields staff, their delivery of outstanding and safe patient care and patient experience. And we fund innovative equipment, facilities and initiatives for improved diagnosis, treatment and patient wellbeing.

Wellbeing of children and their families

Moorfields Eye Charity supports innovation in paediatric patient care and research at Moorfields and UCL. We invest in new technology, equipment, pioneering research and patient wellbeing to help children, including children’s counselling at the hospital. The provision of psychological and emotional therapy for children is vital to supporting them with the impact of sight loss. Thanks to generous support from the Masonic Charitable Foundation we have been able to expand specialist counselling services

for children and young people at Moorfields. Esi Noonoo, counsellor for children and young people, works at Moorfields to provide therapeutic services to children and adolescents – and sometimes the whole family – to help them come to terms with their condition. Working closely with parents is key, and each child is very much shaped by the way their family communicates and copes with their diagnosis. Esi joined Moorfields in September 2016 and saw her first patient in January 2017 after familiarising herself with

all the different departments and setting up the relevant systems and procedures in the hospital. She has learned through her work that the sight loss is not always the main focus of children’s anxieties; instead the focus tends to be on how they perceive themselves and how they think they are perceived by those around them. Much of Esi’s work involves supporting young people with building confidence and making connections while moving through the world following their diagnosis.



£118,759
awarded towards
patient experience and
engagement



£93,983
awarded in clinical
equipment to enhance
clinical care of patients



£1.3 million
invested in two clinical
trials which ultimately aim
to bring improvements in
treatments to patients

Counselling children of all ages

Esi approaches counselling differently depending on the child’s age. For younger children, she uses play therapy, stories and creative activities. These methods fit with how young children express themselves, which means that they don’t have to rely on words, which can be difficult to do at a very young age. During virtual appointments, she ensures that there are plenty of play materials and art supplies – the children love to share their creations with her. Many of the teenagers that access these counselling services experience anxiety around exams, and some also struggle with their identities. These young people often feel isolated and disconnected from peers. It’s also common for them to feel self conscious about needing extra help in school. In order to support them with these difficult emotions, Esi focuses on what their hopes are and how they can begin to take steps towards dealing with their anxieties, building their



self esteem and making connections with others. This involves encouraging them to take relational risks and checking in with them during sessions to see how things are going. Esi feels passionate about being involved in shifting discourses in schools and other institutions around disability and support.

She wants to encourage positive conversations within those contexts that can lead to more inclusive environments. Her hope is that doing so will mean that children with sight loss will feel less isolated. She also aims to continue working closely with schools where appropriate support is not in place.

Patients seen by age group



Article continues from page 15

Vital service in demand

Esi offers a maximum of 24 sessions to allow time to build a therapeutic alliance. These sessions can be face-to-face, online video consultations and even over the phone, as she has learned that some children prefer this medium.

Awareness of Esi's amazing work is growing both inside and outside of Moorfields. Referrals can only be made internally in order to ensure that they are Moorfields' patients, however growth in awareness about the service means that she is receiving referrals for Moorfields' patients across the UK. She has received overwhelmingly positive feedback from patients, their families, and colleagues, demonstrating how invaluable this service is.

It is hugely rewarding to recognise a moment in which a child has taken a step forward in their therapy or realises that they no longer need to speak to me.

Esi Noonoo, Counsellor for children and young people



We would like to thank the Masonic Charitable Foundation for generously funding the expansion of this service.

Digital keys installed in hospital



Digital keys to medicine cupboards have been installed at Moorfields Eye Hospital City Road in the busy A&E

department and in a surgical ward. We're very pleased to support the digital keys and Moorfields staff in the delivery of outstanding and safe patient care through our innovation grant programme. Staff can now access medicines more easily, increasing the time available to care for patients.

Medication is dispensed more efficiently and safely as it helps control drug stocks and creates audit trails. The keys

provide an electronic register of who, when and where medication cupboards have been accessed.

The digital keys have benefits across service improvement, financial efficiencies and improved patient care.

Sarah Needham and her team are evaluating this initiative with plans to roll it out across the entire trust and also for it to become a standard approach in Oriel.



This digital approach has significantly helped us manage medicines. Nurses save up to 40 minutes per shift in wasted time looking for keys, patients get their medication on time and ultimately this gives nurses more time to provide the excellent patient care Moorfields is known for.

Sarah Needham, Deputy chief nurse, Moorfields

Leah and her mum – patient story

What's your connection to Moorfields?

It was at Moorfields Eye Hospital that they found a tumour in my mum Joanne's right eye when she went for a check-up. They're now looking after her and managing her treatment.

What does Moorfields mean to you?

Moorfields means a lot to my mum and me as they have saved and prolonged her life so she can see her children and beautiful grandchildren grow up. If they hadn't given her the care she needed, then I don't know where she'd be now!

Why is it important to you for the charity to be supporting patient care?

It is important to us because without them people would suffer with major eye problems. The charity helps Moorfields buy equipment for better treatments, helping everyone they can, so other families like us don't have to worry.

Leah, her brother Nicci and godmother Andie are taking on a skydive to fundraise for Moorfields Eye Charity.



Oscar and his family – patient story

What's your connection to Moorfields?

Our son was referred to Moorfields at five months old as his sight had not developed. This was during lockdown and even during difficult circumstances, the service, support and care was incredible and a diagnosis was soon provided to confirm he has nystagmus.

What does Moorfields mean to you?

Moorfields provides incredible care and treatment and allows us as parents to better understand how we can help our son to enable him to develop and learn with nystagmus.

Why is it important to you for the charity to be supporting patient care?

We felt it was important to fundraise to give back to this incredible service and we hope that, through fundraising, further research will enable other individuals to receive the support and care needed.

Sarah and her husband Shaun took part in Rat Race – a 20 mile obstacle course fundraising for Moorfields Eye Charity.





Objective 4: Supporting sharing knowledge

We support Moorfields and UCL to share their knowledge, and to educate and develop people's expertise.

Our funding provides support for future leaders through the early stages of their career. It can help them start their research training through to developing their own independent research

programme. We also have a strong track record of supporting the developing careers of researchers and sharing of knowledge. The demonstrable impact of our funding on

the work of the researchers we support can contribute towards advancing our understanding of eye and vision problems, improving diagnoses and developing more treatments.

- › Our PhD studentship and research training fellowship schemes provide an opportunity for promising students to complete a high quality PhD.
- › Postdoctoral researchers are funded by our grants, allowing them to continue developing their research experience.
- › Our Springboard Awards help early career researchers to develop novel ideas and generate preliminary data which can allow them to submit larger grant applications and work towards establishing their independence.

Primary research areas for new awards:


Area of work	Total
Genetics/inherited eye disorders	£1,630,881
Macular (including age-related) degeneration	£1,544,036
Multiple (equipment and technology)	£542,328
Glaucoma	£498,000
Adnexal/eye cancer	£408,533
Retinal/back of the eye	£396,001
Paediatrics	£285,107
Corneal/front of the eye	£231,331
Diabetic retinopathy	£124,244
Inflammatory disease	£100,370
Other	£136,962



£257,428 awarded to support tomorrow's experts



11 springboard awards enabled by £1.1 million commitment in novel ideas



£763,217 invested across 6 PhD studentships and 1 clinical research training fellowship

Advances in artificial intelligence

Honorary clinical research fellow Dr Edward Korot was supported by a springboard award from the charity which has put him at the forefront of AI in eye health care. He recently received two of the most prestigious US awards in ophthalmology, the Michels and Head Fellowships, awarded to the top vitreoretinal surgical fellow

in the United States, and the prestigious Gragoudas Award from the (US) Macular Society. We're proud to be funding

world-leading artificial intelligence (AI) innovation in vision research and eye health and to see its impact.

Artificial intelligence, or AI, is an advancement in computing where computer systems learn from data, identify patterns and perform tasks that we would usually consider as needing human intelligence, such as pattern recognition informed decision-making.

Early career research day

There are around 60 early career researchers and 75 PhD students at the UCL Institute of Ophthalmology. We're proud to support many of them and the fourth UCL Institute of Ophthalmology Early Career Research Symposium which took place at the Francis Crick Institute in June 2021 and was also streamed live.

This was an opportunity to showcase their work and learn about other areas of research.

AI and macular degeneration

Dr Edward Korot worked with Professor Pearse Keane, using AI deep learning to classify clinical images of the eyes of patients with age-related macular degeneration (AMD) and other common retinal diseases. Dr Korot and Professor Keane have also worked directly with Google Cloud and provided feedback on new features for the platforms so that other researchers will have access to robust and explainable automated machine learning platforms for medical AI.

Dr Korot's Nature Medicine Intelligence publication from this work highlights the potential of applying automated AI in the clinic. This would reduce the need for clinicians to develop computer programming skills, and



Professor Pearse Keane

enable them to develop their own models without coding.

Findings from this research have already led to three recent publications in the journals of Lancet Digital Health, Nature Machine Intelligence, and Scientific Reports [5].



▮ This research has the potential to open the floodgates to all the clinicians who would like to design their own AI models but can't. Since those clinicians know the problems which need to be addressed, like where patients have barriers to care, and where patients stand to benefit with earlier and more accurate diagnosis, shorter wait times, and through more efficient triage. ▮▮

Dr Edward Korot

What's next

Dr Korot's research and AI has the potential to increase the accuracy of diagnoses, and develop more treatments. It will enable clinicians without extensive computational expertise or resources to not only train their own machine learning models, but also make sense of them.

- › Charity funded PhD student **Phillipa Harding** presented some of her work on **cellular models made from cells donated by patients with microphthalmia (small eyes) and aniridia**.
- › **26 project summaries** were considered by the charity with **Dr Victoria Tovell** receiving a prize for conveying her research in a clear and accessible manner to a lay audience
- › The charity supported the recognition awards for best presentation, poster and lay audience project summary.

We believe it's important to support early career researchers to develop their careers and ideas which will impact on future advances in eye health.

Objective 5: Shaping national policy

We work with Moorfields to shape national policy and increase resources allocated to eye health. We collaborate with other charities and funders. We use our knowledge and expertise to influence national policies, and we mobilise supporters and partners to raise awareness and contribute as influencers.

Government funding boost to research


We are members of the Association of Medical Research Charities (AMRC) and contributed to its #ResearchAtRisk campaign which called for more investment in medical research charities. Whilst the Government has not yet responded with specific funding at the levels which AMRC and its members consider appropriate, the 2021 Spending Review and Budget committed record levels of investment in the UK's research base over the next three years, with research and development spending set to increase by £5 billion to £20 billion per annum by 2024-2025.

A significant proportion of the budget has been allocated to UK Research and Innovation

(UKRI), which will receive over £25 billion across the next three years, reaching over £8.8 billion in 2024-2025, its highest ever level and over £1 billion more than in 2021-2022. This will have a significant impact on opportunities for the world-renowned research partnership that is Moorfields and UCL now and into the future.

■ Sustained investment is so important for research which, by its very nature, takes time. What we think of as overnight cures come from years of prior hard work, effort and funding. This Government commitment is a positive signal about the importance of R&D to the UK's economy. Medical research charities, industry and the public sector are all vital cogs in the complicated network of research funding. Let's keep them strong and able to deliver what we all need to stay as healthy as possible for as long as possible. ■■

Nicola Perrin, Chief executive of the Association of Medical Research Charities



Research and development spending set to increase to £20 billion by 2024-2025

■ This sends an important message about the value of research and development and its impact on patients, including those with sight loss who will benefit from the advances in medicine. This long-term investment will also impact on Oriel and the future of eye health, bringing new discoveries to the people who need them speedily and safely. ■■

Robert Dufton, Chief executive, Moorfields Eye Charity



UKRI to receive over £25 billion across the next three years

Highlights of our year



Launched our revised six-year strategy

Seahorse bioanalyser



Seahorse bioanalyser appeal launched

Charity trustee professor Carrie MacEwen, appointed Dame Commander in the Order of the British Empire (DBE) for services to ophthalmology and healthcare leadership during the Covid-19 response

The first NIHR Moorfields Eye Charity partnership fellowship was awarded to Dr Patrick Yu Wai Man

Elaine Manna's wing walk to fundraise for Moorfields Eye Charity featured on ITV News and in the Hackney Gazette



Rob Stuzer, Marathon des Sables



Award to charity to support youth volunteering at Moorfields Eye Hospital by NHS Charities Together and Department for Culture Media and Sport

Professor Pearse Keane and patient Elaine Manna featured in The Economist film about AI



Publication of AI research by Professor Pearse Keane and Dr Edward Korot in Scientific Reports

Oriel stakeholder showcase

New branded charity hub opens at Moorfields Eye Hospital City Road

Professor Marinko Sarunic, Moorfields Eye Charity professor of advanced ocular imaging started work at UCL

3D printed prosthetic eye in global headlines

Christmas raffle launched

Lab tours virtual event

Patient and supporter won £25,000 in Moorfields Eye Charity lottery

Moorfields Eye Charity Victoria Cohen memorial fellowship awarded to Moorfields consultant Guy Negretti

The Department for Business, Energy and Industrial Strategy support for research

Eye to Eye London and our virtual event, My Eye to Eye - our annual fundraising walk

Rob Stuzer completed the Marathon Des Sables to fundraise for the charity



Mr Singh won £25,000 playing our weekly lottery



The late Victoria Cohen, Ocular oncology consultant

Our supporters

We are particularly grateful to the individuals and organisations set out below, but also the many other supporters who would prefer to remain anonymous, who have supported us during the year.

- The 29th May 1961 Charitable Trust

Mr Masroor Ahmad

Estate of the late Justine Louise Budenz

Peter Butler

Simon Butler

Estate of the late William Archibald Cave

Silvia Cerolini

Estate of the late Anthony Wilfrid Billings Cogdon

Estate of the late Petros Nicolas Constantinides

Danya Gluschove Corby and Gideon Corby in memory of Deborah Corby

EBM Charitable Trust

Yair Einhorn & Naama Goldman

Evans Management Limited

Estate of the late Anne Patricia Fearnley

Laura Fietta

T F C Frost Trust

Mr Gordon Gilby

Mr Albert Hausamman, Hong Kong

Mr Tim Henderson

The Hobson Charity

Estate of the late Hilma Rose Hocking

The Sir Joseph Hotung Charitable Settlement

Estate of the late Roy James Large

Mr and Mrs Stefanos Lekanidis
- Estate of the late Beryl Annie MacCallum

Estate of the late Faridoon Madon

Iva Marioni, in memory of her sister Elia Rosi

Estate of the late Joan Neville Martin

Brian and Jill Moss Charitable Trust

NHS Charities Together

John and Margaret Nolan

Oak Foundation

Thomas Pocklington Trust

Eleanor A. Robbins

Estate of the late Doctor Elaine Clare Ross

Sir Alan Rudge

The Basil Samuel Charitable Trust

Estate of the late Ann Rosemary Sayer

The Schroder Foundation and Family In Memory of Bruno Schroder

Scott (Eredine) Charitable Trust

Karel Sramek and Vera Sramkova

The Peter Stebbings Memorial Charity

Estate of the late (Doreen) Roberta Taylor

The Michael Uren Foundation


Estate of the late Francis Thomas Webber

The Alexander Pigott Wernher Memorial Trust

The Miss Barbara Mary Wilmot Discretionary Trust

Jill Wilshaw

We would like to thank all the Moorfields and UCL staff who have contributed to the charity's continuing success. We would also like to thank our charity engagement volunteers, trustees, committee members and panel members. With your support, we are able to ensure that Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology remain at the forefront of eye care, research and education worldwide and have the greatest possible impact on the global eye health agenda.



References:

[1] Royal National Institute of Blind People (RNIB) website

[2] Selective laser therapy recommended to treat glaucoma and ocular hypertension, National Institute for Health and Care Excellence (NICE) guideline (January 2022)

[3] Association of Medical Research Charities (AMRC) website

[4] Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy (9 December 2020), Science Translational Medicine, Vol 12, Issue 573

[5] A global review of publicly available datasets for ophthalmological imaging: barriers to access, usability, and generalisability (October 2020), The Lancet Digital Health; Code-free deep learning for multi-modality medical image classification (March 2021), Nature Machine Intelligence; Predicting sex from retinal fundus photographs using automated deep learning, (May 2021), Scientific Reports

Find out more about our work investing in life-changing eye health

Get in touch

Tel: 0207 566 2565

Email: moorfields.eyecharity@nhs.net

moorfieldseyecharity.org.uk

Moorfields Eye Charity
162 City Road
London EC1V 2PD



[moorfieldseyecharitylondon](https://www.facebook.com/moorfieldseyecharitylondon)



[@eyecharity](https://twitter.com/eyecharity)



[moorfields_eye_charity](https://www.instagram.com/moorfields_eye_charity)

Registered Charity No 1140679 Registered No 7543237

Moorfields Eye Charity is a charitable company limited
by guarantee and registered in England and Wales
Registered office 162 City Road, London, EC1V 2PD

© July 2022